148 related articles for article (PubMed ID: 38557462)
1. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
[TBL] [Abstract][Full Text] [Related]
2. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
5. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
7. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
[TBL] [Abstract][Full Text] [Related]
8. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
[TBL] [Abstract][Full Text] [Related]
9. Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Gooderham M; Vender R; Crowley J; Hong HC; Feely M; Garrelts A; See K; Konicek B; Green L
Dermatol Ther (Heidelb); 2024 Feb; 14(2):441-451. PubMed ID: 38332436
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
Blauvelt A; Armstrong AW; Langley RG; Gebauer K; Thaçi D; Bagel J; Guenther LC; Paul C; Randazzo B; Flavin S; Hsu MC; You Y; Reich K
J Dermatolog Treat; 2022 Jun; 33(4):2317-2324. PubMed ID: 34348574
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
[TBL] [Abstract][Full Text] [Related]
13. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
[TBL] [Abstract][Full Text] [Related]
14. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.
Ding Y; Li W; Guan X; Liu N; Zhou Y; Li G; Wang X; Wang Z; Xiao X; Yang B; Lv C; Zhang C; Shi Y
Clin Transl Sci; 2023 Oct; 16(10):1803-1814. PubMed ID: 37644777
[TBL] [Abstract][Full Text] [Related]
16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
[TBL] [Abstract][Full Text] [Related]
19. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
Teeple A; Fitzgerald T
J Dermatolog Treat; 2022 Feb; 33(1):518-524. PubMed ID: 32479140
[TBL] [Abstract][Full Text] [Related]
20. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
Teeple A; Muser E
J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
